Medy-Tox Inc.

086900KOSDAQPharmaceuticals

Medy-Tox Inc. (086900, KOSDAQ) reported KRW 247bn revenue in 2025.

Broker research: target prices and ratings

1 report from 1 firm between 2026-08-20 and 2026-08-20. One firm stated a target price: KRW 70,000.

Newest first. Ratings are as each firm stated them, translated into English. "Not stated" means the report carried no value — it is not a zero.

DateTarget priceRatingFirmAnalyst
KRW 70,000Market PerformKiwoom SecuritiesNot stated

Report titles are not shown: the source lists them in Korean only, and we do not publish our own translation of another firm's headline.

This is a record of what brokers published, not investment advice. It is a sample of broker research — the reports our collection picked up, not every report written on this company — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict.

Source: broker reports collected by SeoulMarkets from Naver Finance's research listing and from brokers' own websites, 2026-06-29 to 2026-10-28.

Compare target prices across Korean biotech and pharma stocks →

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20211853493578404Consolidated
20221954737596434Consolidated
20232211710612474Consolidated
20242292016615471Consolidated
20252471716582454Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
202118.7%50.4%69.9%23.1%
202223.9%18.8%72.7%8.4%
20237.8%4.4%77.6%2%
20248.9%7%76.5%3.4%
20256.9%6.3%78.1%3.4%

Revenue moved 33.8% between 2021 and 2025.

Net profit was positive in the 5 most recent consecutive years on file — every year we hold. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 503bn
Close priceKRW 68,900
Listed shares7,298,497
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Workforce — a side measure, not the main one

Employees (2025)753
Women352 (46.7%)
Average tenure5.4 years
Annual pay, menKRW 73,027,337
Annual pay, womenKRW 54,624,795
Pay ratio, women to men74.8%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →